GHRP-6 vs IGF-2

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1

Insulin-like growth factor 2 (IGF-2) is a naturally occurring peptide growth factor structurally homologous to IGF-1 that plays a central role in embryonic development and remains expressed in adult skeletal muscle, where it functions as an autocrine regulator of myoblast differentiation and myocyte maturation downstream of MyoD activation. IGF-2 binds both the IGF-1 receptor (IGF-1R), which mediates PI3K/Akt anabolic signaling, and the mannose-6-phosphate/IGF-2 receptor (M6P/IGF-2R), which targets bound ligand for lysosomal degradation rather than intracellular signal transduction; the balance between these receptor populations influences net downstream anabolic signaling. Preclinical and cell biology research demonstrates that autocrine IGF-2 signaling through IGF-1R is required for normal myocyte maturation, and that TGF-β-mediated suppression of IGF-2 autocrine pathways impairs skeletal muscle differentiation, establishing IGF-2 as a functionally important endogenous anabolic signal in muscle regeneration. IGF-2 has no FDA-approved applications in performance enhancement or muscle anabolism; exogenous administration as a research compound is investigational and no human clinical trials have established safety or efficacy for these uses.